Clinical trials: Influenza Human
Influenza, Human
Jet Injection for Influenza
The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory…
- Trial name
- JIFI (NCT01688921)
- Testing
- AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device
- Where
- 3 sites in United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Influenza
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed…
- Trial name
- NCT02285998
- Testing
- Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine
- Where
- 38 sites in United States
- Volunteers
- 9,003 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
This is a randomized, double-blind, placebo-controlled study that will investigate the safety and clinical activity of a single intravenous (IV) dose of MHAA4549A in adult participants hospitalized with severe influenza A in…
- Trial name
- NCT02293863
- Testing
- MHAA4549A, Oseltamivir
- Where
- 171 sites in Belgium, Brazil and 23 more
- Volunteers
- 168 people
- Sponsor
- Genentech, Inc.
H1N1 Influenza Healthy Volunteers
Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model
Background: Researchers want to see if a new drug reduces flu disease in people treated with this drug versus a placebo. The drug has an antibody that may help the immune system fight the flu. Placebo is only sugar and water.
- Trial name
- CR6261 (NCT02371668)
- Testing
- CR6261
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how…
- Trial name
- NCT03023709
- Testing
- Fluzone®, FluMist®
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00972517
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 8 sites in Germany
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza
This Phase 2 protocol is designed to compare two dose levels of laninamivir octanoate versus placebo. The objectives are to obtain safety and efficacy in adults aged 18 to 64 years who present to clinic with symptomatic…
- Trial name
- Igloo (NCT01793883)
- Testing
- 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate
- Where
- 221 sites in United States, Australia and 14 more
- Volunteers
- 639 people
- Sponsor
- Biota Scientific Management Pty Ltd
Influenza, Human
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.
- Trial name
- NCT02998996
- Testing
- 15 µg HA/strain and 1% Endocine™, 15 µg HA/strain and 2% Endocine™, 15 µg HA/strain
- Where
- 2 sites in Sweden
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Orthomyxovirus Infection
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects.
- Conditions
- Influenza, Orthomyxovirus Infection, Myxovirus Infection
- Trial name
- NCT00775450
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 28 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
- Trial name
- NCT00771615
- Testing
- GSK A/turkey H5N1 Influenza vaccine
- Where
- 10 sites in United States, Canada
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT02381418
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA…
- Trial name
- NCT01147068
- Testing
- 0.5mL Intramuscular Injection
- Where
- 4 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry
The purpose of this pregnancy registry study is to detect and describe abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with any of GlaxoSmithKline (GSK) Biologicals' seasonal Inactivated Influenza…
- Trial name
- NCT02148211
- Testing
- Data collection
- Where
- United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
- Trial name
- NCT03376321
- Testing
- Pimodivir 600 mg, SOC Treatment
- Where
- 269 sites in United States, Argentina and 36 more
- Volunteers
- 334 people
- Sponsor
- Janssen Research & Development, LLC
Influenza
Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Background: Researchers want to know if a certain type of antibody in the blood affects whether people get influenza (the flu). They will study 2 different groups with different levels of anti-HA antibodies and expose them to the…
- Trial name
- NCT01971255
- Testing
- Ca/04/2009/H1N1r Challenge Virus
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
The purpose of this study is to see how the body reacts to different strengths of the H1N1 flu shot in persons infected with human immunodeficiency virus (HIV).
- Trial name
- NCT00992433
- Testing
- Inactivated Influenza H1N1 vaccine
- Where
- 6 sites in United States
- Volunteers
- 192 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03023176
- Testing
- Fluzone® standard IIV3, Fluzone® standard IIV3 Pediatric Dose
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza…
- Trial name
- NCT01884519
- Testing
- Fluarix/Influsplit SSW® (2013-2014 season)
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline